Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biodesix, a molecular diagnostics company, has received three additional patents from the US Patent & Trademark Office (PTO) and the European Patent Office for blood-based oncology tests.
Subscribe to our email newsletter
USPTO granted two patents which provide intellectual property protection for methods relating to the company’s products and technology, while the European Patent Office granted a patent providing coverage for Biodesix’s VeriStrat, for the selection of patients for drug therapy.
VeriStrat is a serum proteomic test currently available in the US that enabled physicians to guide therapy for patients with advanced lung cancer.
European patent covers the use of VeriStrat for selection of head and neck cancer patients for treatment with targeted drugs.
US patent provides additional intellectual property protection for the methods used with VeriStrat which are related to Biodesix’ ProTS technology.
Biodesix CEO David Brunel said the issuance of patents reflects the company’s global strategy to protect VeriStrat and their technology platform.
"This protection strengthens our commercial position as a leading provider of diagnostics to personalize medicine for oncology patients," Brunel added.